Amneal Pharmaceuticals, Inc.
AMRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $2,794 | $2,394 | $2,212 | $2,094 |
| % Growth | 16.7% | 8.2% | 5.7% | – |
| Cost of Goods Sold | $1,774 | $1,530 | $1,421 | $1,325 |
| Gross Profit | $1,020 | $864 | $791 | $769 |
| % Margin | 36.5% | 36.1% | 35.8% | 36.7% |
| R&D Expenses | $191 | $195 | $209 | $210 |
| G&A Expenses | $442 | $417 | $383 | $0 |
| SG&A Expenses | $476 | $430 | $400 | $366 |
| Sales & Mktg Exp. | $34 | $12 | $17 | $0 |
| Other Operating Expenses | $104 | $35 | $278 | $41 |
| Operating Expenses | $771 | $659 | $886 | $616 |
| Operating Income | $249 | $204 | -$95 | $153 |
| % Margin | 8.9% | 8.5% | -4.3% | 7.3% |
| Other Income/Exp. Net | -$304 | -$245 | -$153 | -$121 |
| Pre-Tax Income | -$55 | -$40 | -$248 | $31 |
| Tax Expense | $19 | $8 | $7 | $11 |
| Net Income | -$117 | -$84 | -$130 | $11 |
| % Margin | -4.2% | -3.5% | -5.9% | 0.5% |
| EPS | -0.38 | -0.48 | -0.86 | 0.07 |
| % Growth | 20.8% | 44.2% | -1,328.6% | – |
| EPS Diluted | -0.38 | -0.48 | -0.86 | 0.07 |
| Weighted Avg Shares Out | 309 | 175 | 151 | 149 |
| Weighted Avg Shares Out Dil | 309 | 176 | 151 | 152 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $158 | $0 |
| Interest Expense | $259 | $211 | $158 | $136 |
| Depreciation & Amortization | $236 | $229 | $240 | $233 |
| EBITDA | $440 | $501 | $440 | $401 |
| % Margin | 15.7% | 20.9% | 19.9% | 19.2% |